Caboxen is identified as a cabozantinib product available in 20 mg and 80 mg strengths. Cabozantinib is a targeted anticancer medicine belonging to the tyrosine kinase inhibitor (TKI) class.
It works by blocking several proteins involved in cancer-cell growth, survival, migration, and tumor-associated blood-vessel formation.
Cabozantinib is used to treat selected types of cancer, depending on the formulation, disease characteristics, previous treatments, and applicable regulatory approval.
This page explains the established therapeutic uses of cabozantinib, its mechanism of action, treatment considerations, potential benefits, and important safety precautions.
Important: The exact dosage form, manufacturer, and product-specific regulatory authorization of Caboxen have not been independently confirmed. The indications described below refer to established cabozantinib reference products and should not automatically be attributed to Caboxen.
1. What Is Cabozantinib Used For?
Cabozantinib has established uses in several cancer-treatment settings.
These include:
- Advanced renal cell carcinoma.
- Hepatocellular carcinoma.
- Differentiated thyroid cancer.
- Selected pancreatic neuroendocrine tumors.
- Selected extra-pancreatic neuroendocrine tumors.
- Progressive metastatic medullary thyroid cancer.
The approved uses differ between cabozantinib tablets and capsules.
2. Caboxen for Renal Cell Carcinoma
Renal cell carcinoma (RCC) is the most common type of kidney cancer. It develops when abnormal cells grow in kidney tissue.
Advanced renal cell carcinoma may spread beyond the kidney to other parts of the body.
Cabozantinib tablets are used in specified patients with advanced renal cell carcinoma.
How Does Cabozantinib Work in Kidney Cancer?
Cabozantinib inhibits several receptor tyrosine kinases involved in cancer progression.
Its activity against VEGF receptors may interfere with tumor-associated blood-vessel formation.
Its activity against MET and AXL may interfere with signaling pathways associated with cancer-cell survival, migration, and progression.
Treatment Options
Depending on the patient’s condition and applicable approval, cabozantinib tablets may be prescribed:
- As a single-agent treatment for eligible patients.
- In combination with nivolumab for eligible patients with advanced renal cell carcinoma.
The appropriate treatment regimen is determined by the oncology team.
3. Caboxen for Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver.
It develops from hepatocytes, the main functional cells of the liver.
Cabozantinib tablets are indicated for certain patients with hepatocellular carcinoma who have previously received sorafenib.
How Does Cabozantinib Work in Liver Cancer?
Cabozantinib inhibits multiple molecular targets involved in tumor growth and angiogenesis.
By interfering with VEGF receptor signaling and other cancer-related pathways, it may help control disease progression in eligible patients.
Important Treatment Considerations
Before prescribing cabozantinib, healthcare professionals may evaluate:
- Liver function.
- Previous cancer treatment.
- Disease progression.
- General health.
- Blood pressure.
- Other existing medical conditions.
- Potential drug interactions.
Liver function monitoring is particularly important during treatment.
4. Caboxen for Differentiated Thyroid Cancer
Differentiated thyroid cancer (DTC) develops from thyroid cells that retain certain characteristics of normal thyroid tissue.
Common forms include:
- Papillary thyroid cancer.
- Follicular thyroid cancer.
- Hürthle cell carcinoma.
Cabozantinib tablets are approved for specified patients with locally advanced or metastatic differentiated thyroid cancer that has progressed following previous VEGFR-targeted therapy and is radioactive iodine-refractory or unsuitable for radioactive iodine treatment.
How Does Cabozantinib Work in Thyroid Cancer?
Cabozantinib inhibits several receptor tyrosine kinases involved in tumor growth and blood-vessel formation.
Its multi-target activity may interfere with signaling pathways that contribute to disease progression.
Treatment Assessment
The oncology team evaluates the patient’s previous treatment, disease progression, and overall health before considering cabozantinib.
Treatment response is assessed through appropriate clinical examinations and imaging investigations.
5. Caboxen and Neuroendocrine Tumors
Neuroendocrine tumors (NETs) develop from cells that have characteristics of both nerve cells and hormone-producing cells.
They can occur in different organs, including the pancreas and gastrointestinal tract.
Cabozantinib tablets have an approved role in certain previously treated, unresectable, locally advanced, or metastatic well-differentiated pancreatic and extra-pancreatic neuroendocrine tumors.
Pancreatic Neuroendocrine Tumors
Pancreatic neuroendocrine tumors develop from hormone-producing cells within the pancreas.
Some tumors grow slowly, while others may progress and spread to other organs.
Cabozantinib tablets may be considered for eligible patients in the approved treatment setting.
Extra-Pancreatic Neuroendocrine Tumors
Extra-pancreatic neuroendocrine tumors develop outside the pancreas.
They may originate in the gastrointestinal tract, lungs, or other organs.
Cabozantinib tablets have an approved treatment role in certain previously treated patients with unresectable, locally advanced, or metastatic well-differentiated disease.
The prescribing oncologist determines whether treatment is appropriate.
6. Cabozantinib for Medullary Thyroid Cancer
Medullary thyroid cancer (MTC) is a relatively uncommon type of thyroid cancer that develops from parafollicular C cells.
These cells produce calcitonin, a hormone involved in calcium regulation.
A separate cabozantinib capsule formulation is approved for progressive metastatic medullary thyroid cancer.
How Does Cabozantinib Work in Medullary Thyroid Cancer?
Cabozantinib inhibits several receptor tyrosine kinases, including RET, MET, and VEGF receptors.
These targets participate in signaling pathways associated with cellular growth and tumor development.
Its multi-target activity contributes to its therapeutic role in the approved treatment setting.
Formulation distinction: The medullary thyroid cancer indication is associated with the reference capsule product. It should not automatically be applied to a cabozantinib tablet product or Caboxen without product-specific authorization.
7. How Cabozantinib Works Against Cancer
Cabozantinib is a multi-targeted tyrosine kinase inhibitor.
It blocks several proteins that contribute to cancer-related biological processes.
VEGFR Inhibition
VEGF receptors regulate angiogenesis, which is the formation of new blood vessels.
Tumors may stimulate blood-vessel formation to obtain oxygen and nutrients.
Cabozantinib inhibits VEGF receptor signaling and interferes with pathways involved in tumor-associated angiogenesis.
MET Inhibition
MET is involved in cellular growth, survival, and movement.
Abnormal MET signaling may contribute to tumor progression.
Cabozantinib inhibits MET activity and may interfere with these cancer-related processes.
AXL Inhibition
AXL participates in cell survival, migration, and interactions between cancer cells and surrounding tissues.
Its inhibition contributes to the broader pharmacological activity of cabozantinib.
RET and KIT Inhibition
RET and KIT are receptor tyrosine kinases involved in cellular signaling and development.
Cabozantinib also inhibits these targets, contributing to its multi-target mechanism.
8. Potential Benefits of Cabozantinib Treatment
When prescribed for an appropriate indication, cabozantinib may provide several potential therapeutic benefits.
These include:
- Inhibition of multiple cancer-related signaling pathways.
- Interference with tumor-associated angiogenesis.
- Activity against selected molecular targets.
- Potential control of cancer progression.
- Use in certain advanced cancer-treatment settings.
- Use as monotherapy or in selected combination regimens.
The degree of benefit varies between patients.
Cabozantinib does not guarantee complete tumor elimination or a permanent cure.
9. Who May Be Eligible for Cabozantinib Treatment?
Eligibility depends on the specific cancer diagnosis and approved treatment setting.
The oncology team may consider:
- Confirmed cancer type.
- Disease stage.
- Tumor characteristics.
- Previous treatments.
- Disease progression.
- Liver and kidney function.
- Blood pressure.
- Other medical conditions.
- Potential drug interactions.
- Ability to tolerate treatment.
Not every patient with one of the cancer types described above is automatically eligible for cabozantinib.
10. Cabozantinib Dosage for Different Cancer Types
The prescribed dose depends on the cancer, formulation, and treatment regimen.
The following table summarizes reference regimens for established cabozantinib products.
| Cancer or treatment setting | Reference formulation | Reference regimen |
|---|---|---|
| Advanced RCC, monotherapy | Tablets | 60 mg once daily |
| Advanced RCC with nivolumab | Tablets | 40 mg once daily |
| Specified HCC treatment | Tablets | 60 mg once daily |
| Specified DTC treatment | Tablets | 60 mg once daily |
| Specified NET treatment | Tablets | 60 mg once daily |
| Progressive metastatic MTC | Capsules | 140 mg once daily |
These are reference-product regimens, not recommendations for Caboxen.
Dose reductions or interruptions may be necessary because of adverse reactions, interactions, or individual medical circumstances.
11. How to Take Cabozantinib
Cabozantinib is administered orally in established tablet and capsule formulations.
However, administration instructions differ between the formulations.
Tablet Administration
For the reference tablet formulation:
- Take on an empty stomach.
- Take at least one hour before food or at least two hours after food.
- Swallow tablets whole.
- Do not crush, chew, or split tablets.
- Follow the prescribed treatment schedule.
Capsule Administration
For the reference capsule formulation:
- Avoid food for at least two hours before administration.
- Take the prescribed capsules with water.
- Avoid food for at least one hour after administration.
- Follow the prescribed schedule.
Patients must follow the instructions for their confirmed product rather than combining tablet and capsule instructions.
12. Common Side Effects During Treatment
Cabozantinib may cause adverse reactions that affect daily activities and overall treatment tolerance.
Commonly reported side effects include:
- Diarrhea.
- Fatigue.
- Nausea.
- Vomiting.
- Decreased appetite.
- Weight loss.
- Hypertension.
- Hand-foot skin reactions.
- Mouth sores.
- Constipation.
- Abdominal discomfort.
- Changes in taste.
- Voice changes.
Patients should report persistent or worsening symptoms to their healthcare professional.
13. Serious Safety Risks
Cabozantinib can cause serious and potentially life-threatening complications.
Important risks include:
| Adverse reaction | Important symptoms |
|---|---|
| Severe bleeding | Vomiting blood, black stools |
| Gastrointestinal perforation | Severe abdominal pain |
| Fistula | Abnormal connection between organs |
| Blood clots | Chest pain, leg swelling, breathing difficulty |
| Severe hypertension | Severe headache, visual changes |
| Liver toxicity | Jaundice, dark urine |
| Proteinuria | Abnormal protein in urine |
| Osteonecrosis of the jaw | Persistent jaw pain, exposed bone |
| Impaired wound healing | Delayed surgical recovery |
| RPLS/PRES | Seizures, confusion, visual disturbances |
Seek urgent medical attention if serious symptoms develop.
14. Drug Interactions
Cabozantinib is metabolized through the CYP3A4 pathway.
Certain medicines may change the amount of cabozantinib in the body.
CYP3A4 Inhibitors
Strong CYP3A4 inhibitors may increase cabozantinib exposure and the risk of adverse reactions.
CYP3A4 Inducers
Strong CYP3A4 inducers may decrease cabozantinib exposure and potentially reduce treatment effectiveness.
Patients should disclose all medicines, vitamins, supplements, and herbal products to their healthcare professional.
15. Monitoring During Treatment
Regular monitoring is important for patients receiving cabozantinib.
Healthcare professionals may assess:
- Blood pressure.
- Liver function.
- Kidney function.
- Urine protein.
- Blood counts and relevant laboratory values.
- Calcium levels.
- Thyroid function.
- Skin reactions.
- Gastrointestinal symptoms.
- Dental health.
- General treatment tolerance.
- Cancer response.
Monitoring schedules should be individualized.
16. When Should Treatment Be Interrupted?
The prescribing oncologist may recommend temporarily interrupting or reducing cabozantinib if serious adverse reactions develop.
Treatment modification may be necessary for:
- Severe diarrhea.
- Uncontrolled hypertension.
- Significant hand-foot skin reactions.
- Serious bleeding.
- Liver abnormalities.
- Proteinuria.
- Gastrointestinal perforation.
- Fistula formation.
- Other clinically significant toxicities.
Patients should never independently stop, restart, or change their prescribed dose.
17. Frequently Asked Questions About Caboxen Uses and Treatment
1. What cancers can cabozantinib treat?
Depending on the formulation and regulatory approval, cabozantinib has established uses in selected patients with renal cell carcinoma, hepatocellular carcinoma, differentiated thyroid cancer, neuroendocrine tumors, and medullary thyroid cancer.
2. Is Caboxen used for kidney cancer?
Cabozantinib tablets are used in specified patients with advanced renal cell carcinoma. Caboxen’s product-specific authorization for this indication requires verification.
3. Can cabozantinib treat liver cancer?
Cabozantinib tablets are approved for certain patients with hepatocellular carcinoma who have previously received sorafenib.
4. Is cabozantinib used for thyroid cancer?
Yes. Different reference formulations have established uses in specified patients with differentiated thyroid cancer and progressive metastatic medullary thyroid cancer.
5. Can cabozantinib treat neuroendocrine tumors?
Cabozantinib tablets have an approved role in certain previously treated, unresectable, locally advanced, or metastatic well-differentiated pancreatic and extra-pancreatic neuroendocrine tumors.
6. How does cabozantinib fight cancer?
It inhibits several receptor tyrosine kinases involved in tumor growth, cell survival, migration, and blood-vessel formation.
7. Is cabozantinib a targeted therapy?
Yes. Cabozantinib is classified as a multi-targeted tyrosine kinase inhibitor.
8. Can cabozantinib be combined with immunotherapy?
Yes. Cabozantinib tablets are used with nivolumab in an approved treatment setting for eligible patients with advanced renal cell carcinoma.
9. Does cabozantinib cure cancer?
Cabozantinib is not a guaranteed cure. It may help control certain cancers and delay disease progression in eligible patients.
10. How long does cabozantinib treatment continue?
Treatment duration depends on disease response, adverse reactions, and the treating oncologist’s assessment.
11. Are cabozantinib tablets and capsules interchangeable?
No. They are not bioequivalent and have different administration requirements and approved indications.
12. Can I take Caboxen without medical supervision?
No. Cabozantinib requires a valid prescription, specialist supervision, and regular monitoring.
18. Important Information About Caboxen
| Product detail | Information |
|---|---|
| Brand name | Caboxen |
| Active ingredient stated | Cabozantinib |
| Presented strengths | 20 mg and 80 mg |
| Drug class | Tyrosine kinase inhibitor |
| Therapeutic category | Anticancer medicine |
| Route | Oral |
| Dosage form | – |
| Manufacturer | – |
| Regulatory authorization | – |
| Prescription requirement | Yes |
Final Medical Disclaimer
Caboxen is identified as a cabozantinib product in 20 mg and 80 mg strengths. However, its exact dosage form, manufacturer, regulatory authorization, and product-specific approved indications require independent confirmation.
The treatment indications and dosage information described on this page relate to established cabozantinib reference products. They must not be used as a substitute for Caboxen-specific prescribing information.
Cabozantinib can cause serious adverse reactions and should only be prescribed by qualified healthcare professionals experienced in cancer treatment.